Fig. 1: RIPK1 and MLKL expression are associated with poor clinical outcomes in gliomas.
From: Necroptotic signaling orchestrates glioblastoma malignancy and potentiates temozolomide response
mRNA expression levels of RIPK1, RIPK3, and MLKL in the TCGA glioma cohort with WHO grade II–IV (G2–G4, A) or IDH mutation status (B). C, D Protein levels of RIPK1, RIPK3, and MLKL in 81 clinical glioma samples grouped by 1p/19q codeletion status. E mRNA expression of RIPK1, RIPK3, and MLKL in gliomas (G2–G4) versus normal brain tissue. F Heatmap of hazard ratios (HRs) for overall survival (OS) comparing high versus low expression of RIPK1, RIPK3, and MLKL across 23 cancer types. G Kaplan-Meier OS curves (High vs. Low) for patients stratified by different protein levels of RIPK1, RIPK3, or MLKL in gliomas. The 81 patients with G2–G4 gliomas were reviewed retrospectively, and protein expression levels were collected from Fig. S2. Data are presented as mean ± SD. Comparisons between two groups were performed using the Wilcoxon rank-sum test. *p < 0.05, **p < 0.01, ***p < 0.001, ns no significance.
